Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ALPPL2 CRISPR/Cas9 KO Plasmid (h2): sc-401492-KO-2
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ALPPL2 CRISPR/Cas9 Knockout (KO) Plasmid (h2) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ALPPL2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ALPPL2 Antibody (9-YD35): sc-134255
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ALPPL2 CRISPR/Cas9 KO Plasmid (h2) | sc-401492-KO-2 | 20 µg | $397.00 |
Overview
ALPPL2 encodes alkaline phosphatase, placental-like 2, a glycosylphosphatidylinositol-anchored ectoenzyme that hydrolyzes phosphate monoesters at the cell surface. By regulating dephosphorylation of extracellular substrates, ALPPL2 can influence local phosphate availability, membrane microdomain signaling, and differentiation-associated programs, particularly in epithelial and germ cell–related contexts. Its expression is frequently used as a marker of specific developmental states, and altered ALPPL2 expression has been reported in multiple cancer-related datasets. These features make ALPPL2 relevant for studies of cell identity, surface enzyme biology, and pathway remodeling during transformation.
ALPPL2 CRISPR/Cas9 KO Plasmid (h2) is a pool of plasmids designed for targeted disruption of the ALPPL2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ALPPL2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ALPPL2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ALPPL2 protein expression.
This CRISPR knockout system enables efficient generation of ALPPL2-deficient cell models for investigation of ALPPL2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ALPPL2 exon(s) critical for ALPPL2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ALPPL2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ALPPL2 CRISPR/Cas9 KO Plasmid (h) and ALPPL2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ALPPL2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ALPPL2 HDR Plasmid (h) and ALPPL2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ALPPL2 homology arms to support homology-directed repair at defined ALPPL2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.